Refractive and structural changes in infantile periocular capillary haemangioma treated with propranolol

Snir, Moshe; Reich, U; Siegel, Ronald K.; Zvulunov, Alex; Friling, Ronit; Goldenberg-Cohen, Nitza; Ron, Yonina; Ben-Amitay, D

doi:10.1038/eye.2011.233

Cited by 28 publications

(24 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other specified indications included rapid growth, potentially life-threatening complications, segmental distribution, psychosocial stress, failure of systemic corticosteroids, and avoidance of aggressive and potentially scarring procedures. Two-thirds of the studies included IHs in multiple anatomic sites, whereas one-third focused on IHs in specific locations, such as periorbital (6)(7)(8)(9)(10)(11)(12), airway (13), parotid (14), face (15,16), and head and neck (17,18).…”

Section: Resultsmentioning

confidence: 99%

Propranolol and Infantile Hemangiomas Four Years Later: A Systematic Review

Marqueling

Oza

Frieden

et al. 2013

Pediatric Dermatology

228

203

View full text Add to dashboard Cite

To systematically review the literature evaluating efficacy and adverse events of propranolol treatment for infantile hemangiomas, we searched the MEDLINE and Cochrane databases for all studies examining the response of infantile hemangiomas (IHs) to propranolol published between June 12, 2008, and June 15, 2012. Forty-one studies with 1,264 patients were included; 74% of patients were female and approximately 30% had received other treatments before propranolol. Propranolol was initiated at a mean age of 6.6 months at a mean dose of 2.1 mg/kg/day and for a mean treatment duration of 6.4 months. The response rate for patients with IHs treated with propranolol was 98% (range 82%-100%), with response rate defined as any improvement with propranolol. Treatment response rates were comparable for studies evaluating IHs at specific sites, such as periorbital IHs. Studies that followed patients after treatment completion reported IH rebound growth in 17% of patients. There were 371 adverse events reported in 1,189 patients. The most common adverse events were changes in sleep (n = 136) and acrocyanosis (n = 61). Serious adverse events were rare, with reports of symptomatic hypotension in five patients, hypoglycemia in four, and symptomatic bradycardia in one. This systematic review of 1,264 patients treated with propranolol for IHs showed a high rate of efficacy and a low rate of serious adverse events.

show abstract

Section: Resultsmentioning

confidence: 99%

Propranolol and Infantile Hemangiomas Four Years Later: A Systematic Review

Marqueling

Oza

Frieden

et al. 2013

Pediatric Dermatology

228

203

View full text Add to dashboard Cite

show abstract

“…Several cases in the literature report successful treatment of periocular infantile hemangiomas . However, there are only a few reports on the treatment of episcleral hemangiomas .…”

Section: Discussionmentioning

confidence: 99%

Episcleral infantile hemangioma successfully treated with topical timolol

et al. 2014

View full text Add to dashboard Cite

show abstract

“…7,[34][35][36] Visible changes between the 1 st and the 3 rd day of therapy are explained with vasospasms following the reduction of nitric oxide release. 4 In the study group, a change of color or reduction of tension in the 1 st week of treatment was observed in 70% of patients, while at the end of the 1 st month it was noted in over 90% of children.…”

Section: Resultsmentioning

confidence: 99%

“…The treatment should last 6-8 months, but may be extended to 1-2 years. 7,8,34,35 The treatment should be continued until the end of the proliferative phase, to a minimum of 1 year of age, and in periocular hemangiomas until the defect (astigmatism) is corrected. 35,37,38 Too early or rapid withdrawal may result in recurrence.…”

Section: Resultsmentioning

confidence: 99%

Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children: Are we closer to understand the mechanism of action of propranolol on hemangiomas?

et al. 2018

View full text Add to dashboard Cite

Background. Propranolol has become the treatment of choice for infantile hemangiomas (IH). Neither the pathogenesis of IH nor the mechanism of action of propranolol on them are well understood. Possible explanations include the inhibition of angiogenesis by decreasing vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), induction of vascular endothelial cell apoptosis and vasoconstriction.

show abstract

Refractive and structural changes in infantile periocular capillary haemangioma treated with propranolol

Cited by 28 publications

References 36 publications

Propranolol and Infantile Hemangiomas Four Years Later: A Systematic Review

Propranolol and Infantile Hemangiomas Four Years Later: A Systematic Review

Episcleral infantile hemangioma successfully treated with topical timolol

Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children: Are we closer to understand the mechanism of action of propranolol on hemangiomas?

Contact Info

Product

Resources

About